2-苯氧基烟酸 | 35620-71-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-苯氧基烟酸
• 英文名称: 2-Phenoxy-nicotinsaeure
• 英文别名: 2-phenoxynicotinic acid；2-phenoxypyridine-3-carboxylic acid
• CAS: 35620-71-4
• 化学式: C₁₂H₉NO₃
• mdl: MFCD00014629
• 分子量: 215.208
• InChiKey: CQGAXJGXGLVFGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  172-175 °C
• 沸点：
  355.48°C (rough estimate)
• 密度：
  1.2521 (rough estimate)
• 稳定性/保质期：
  常规情况下不会分解，也没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 安全说明：
  S26,S37
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	2-Phenoxynicotinic acid Material Safety Data Sheet
Synonym:	None Known
CAS:	35620-71-4

Section 1 - Chemical Product MSDS Name:2-Phenoxynicotinic acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
35620-71-4	2-Phenoxynicotinic acid	98%	252-647-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 35620-71-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 177-179 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H9NO3
Molecular Weight: 215.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide, nitric acid.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 35620-71-4: US5902372 LD50/LC50:
Not available.
Carcinogenicity:
2-Phenoxynicotinic acid - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 35620-71-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 35620-71-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 35620-71-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯氧基烟酸 在 PPA 作用下， 反应 16.0h， 生成 阿扎那托
  参考文献：
  名称：

  Benzopyranopyridine derivatives. 1. Aminoalkyl derivatives of the azaxanthenes as bronchodilating agents

  摘要：

  The preparation of the four isomeric azaxanthones 3 and a number of their aromatic ring substituted derivatives is described. These ketones were converted into the title compounds which were examined for their biological properties. The most interesting compound in this series, the 1-methyl-4-piperidylidene derivative of 1-azaxanthene, shows the profile of an orally effective potent bronchodilating agent as well as a moderate antihistamine. Biological properties of this compound were compared to a number of antihistamines as well as known bronchodilating agents. Structure-activity relationships are also discussed.

  DOI：

  10.1021/jm00235a001
• 作为产物：
  描述：

  2-羟基烟酸 在 五氯化磷 、 sodium methylate 、 三氯氧磷 作用下， 生成 2-苯氧基烟酸
  参考文献：
  名称：

  163.氧杂蒽酮和噻吨酮。第二部分 噻吨氧基，9-蒽胺和9-噻吨胺的衍生物

  摘要：

  DOI：

  10.1039/jr9510000757
• 作为试剂：
  描述：

  2-氯烟酸 、 苯氧基自由基 、 苯酚 在 2-苯氧基烟酸 、 polyphosphoric acid 、 水 、 alkali hydroxide 作用下， 以 水 为溶剂， 以obtaining very pure 1-azaxanthone in an overall yield of 50-70%的产率得到1-azaxanthone
  参考文献：
  名称：

  1-azaxanthone for use as therapeutic agent as an antipyretic, analgesic,

  摘要：

  环闭合法制备1-氮杂黄酮及其作为治疗剂的用途。

  公开号：

  US04623648A1

文献信息

• Carboxyl radical-assisted 1,5-aryl migration through Smiles rearrangement
  作者：Asik Hossian、Ranjan Jana

  DOI：10.1039/c6ob01758d

  日期：——

  We report herein, a silver(I)-catalyzed Smiles rearrangement of 2-aryloxy- or 2-(arylthio)benzoic acids to provide aryl-2-hydroxybenzoate or aryl-2-mercaptobenzoate dimer, respectively, through 1,5-aryl migration from oxygen or sulfur to carboxylate oxygen. Mechanistically, the aryl ether moiety undergoes an intramolecular ipso attack by the carboxyl radical followed by a C–O or C–S bond cleavage.

  我们在此报告，通过1,5-芳基迁移，通过银（I）催化的2-芳氧基-或2-（芳硫基）苯甲酸的Smiles重排以分别提供芳基-2-羟基苯甲酸酯或芳基-2-巯基苯甲酸酯二聚体。从氧或硫到羧化氧。从机理上讲，芳基醚部分受到羧基的分子内ipso攻击，然后发生C–O或C–S键断裂。芳基-2-巯基苯甲酸酯通过原位硫醇部分进行氧化二聚。
• Substituted pyridines having antiangiogenic activity
  申请人：——

  公开号：US20040014744A1

  公开（公告）日：2004-01-22

  Compounds having the formula 1 are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物是抑制血管生成的抑制剂。还公开了含有这些化合物的组合物、制备这些化合物的方法以及使用这些化合物进行治疗的方法。
• Selective Inhibition of DNA Polymerase β by a Covalent Inhibitor
  作者：Shelby C. Yuhas、Daniel J. Laverty、Huijin Lee、Ananya Majumdar、Marc M. Greenberg

  DOI：10.1021/jacs.1c02453

  日期：2021.6.2

  has been closely linked to cancer. Selective inhibitors of this enzyme are lacking. Inspired by DNA lesions produced by antitumor agents that inactivate Pol β, we have undertaken the development of covalent small-molecule inhibitors of this enzyme. Using a two-stage process involving chemically synthesized libraries, we identified a potent irreversible inhibitor (14) of Pol β (KI = 1.8 ± 0.45 μM, kinact

  DNA 聚合酶 β (Pol β) 在 DNA 修复中起着至关重要的作用，并且与癌症密切相关。缺乏这种酶的选择性抑制剂。受使 Pol β 失活的抗肿瘤剂产生的 DNA 损伤的启发，我们着手开发这种酶的共价小分子抑制剂。使用涉及化学合成文库的两阶段过程，我们确定了Pol β的有效不可逆抑制剂 ( 14 ) ( K I = 1.8 ± 0.45 μM, k inact = (7.0 ± 1.0) × 10 –3 s –1 )。抑制剂14比其他 DNA 聚合酶选择性地灭活 Pol β。用14处理的 Pol β 胰蛋白酶消化物的 LC-MS/MS 分析鉴定了聚合酶结合位点内共价修饰的两个赖氨酸，其中一个先前被确定在DNA结合中起作用。荧光各向异性实验表明，用14预处理 Pol β可防止 DNA 结合。在野生型小鼠胚胎成纤维细胞 (MEF) 中使用前抑制剂 ( pro - 14 ) 的实验表明，抑制剂
• Synthesis and pharmacological study of N-(2-substituted-nicotinoyl) amino acids
  作者：L. A. Zhmurenko、S. A. Borisenko、O. M. Glozman、R. U. Ostrovskaya、Yu. V. Burov、V. A. Zagorevskii

  DOI：10.1007/bf01156373

  日期：1980.9

  nicotinic acid in the treatment of certain psychic ailments has served as the basis for a search for new psyochotropic substances based on nicotonic acid [1]. Thus, N-nicotinoyl-~aminobutyric acid (N-nicotinoyl-GABA) displays a high physiological activity [2]; and another nicotinic acid de r i va t i ve -n i c o l i t e exe r t s a tranquilizing action [3, 4]. One of the trends in the search for pharmacologically

  烟酸在治疗某些精神疾病方面的治疗作用已成为寻找以烟酸为基础的新型精神疗法物质的基础[1]。因此，N-烟酰-~氨基丁酸（N-烟酰-GABA）显示出很高的生理活性[2]；和另一种烟酸 de ri va ti ve -nicolite exe rtsa 镇静作用 [3, 4]。在烟酸衍生物中寻找药理活性物质的趋势之一是引入各种取代基，特别是在吡啶环的 2 或 4 位，结果已确定 2 '烟酸的苯胺基衍生物显示出明确的抗惊厥和镇痛活性 [5, 6]；其中一些是利血平拮抗剂并增强苯丙胺的作用 [5]，
• 5- substituted tetralones as inhibitors of ras farnesyl trransferase
  申请人：——

  公开号：US20040044057A1

  公开（公告）日：2004-03-04

  The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme. 1

  本发明提供了式(I)、(II)、(III)和(IV)的新型5-取代四酮及其药学上可接受的盐、酯、酰胺和前药，用于治疗和预防组织的不受控制或异常增殖，如癌症、动脉粥样硬化、再狭窄和银屑病。具体而言，本发明涉及抑制法尼基转移酶酶的化合物。

表征谱图